Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS

  • Original Article
  • Published:
Tumor Biology

Abstract

MicroRNAs (miRNAs) play several important roles in carcinogenesis, and the dysregulation of miRNAs is associated with cancer progression. Little is known about the role of miR-613 in ovarian cancer. In the present study, we demonstrate that miR-613 expression is downregulated in human ovarian cancer cell lines and tissues. Additionally, miR-613 overexpression suppressed ovarian cancer cell proliferation, colony formation, and invasion. Furthermore, KRAS was identified as a target of miR-613. Reintroducing KRAS rescued the inhibitory effects exerted by miR-613 on ovarian cancer cell proliferation and invasion. Taken together, our findings suggest that miR-613 functions as a candidate tumor suppressor miRNA in ovarian cancer by directly targeting KRAS. To the best of our knowledge, this is the first study to show that miR-613 affects the proliferation and invasion of ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Maldonado L, Hoque MO. Epigenomics and ovarian carcinoma. Biomark Med. 2010;4:543–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Davidson B, Trope CG, Reich R. The clinical and diagnostic role of microRNAs in ovarian carcinoma. Gynecol Oncol. 2014;133:640–6.

    Article  CAS  PubMed  Google Scholar 

  3. Montopoli M, Ragazzi E, Froldi G, Caparrotta L. Cell-cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells. Cell Prolif. 2009;42:195–206.

    Article  CAS  PubMed  Google Scholar 

  4. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, et al. miR-145 inhibits tumor growth and metastasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget. 2014;5:10816–29.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Tang Z, Ow GS, Thiery JP, Ivshina AV, Kuznetsov VA. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma. Int J Cancer. 2014;134:306–18.

    Article  PubMed  Google Scholar 

  6. Hirata Y, Murai N, Yanaihara N, Saito M, Urashima M, Murakami Y, et al. MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma. BMC Cancer. 2014;14:799.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Tang H, Yao L, Tao X, Yu Y, Chen M, Zhang R, et al. miR-9 functions as a tumor suppressor in ovarian serous carcinoma by targeting tln1. Int J Mol Med. 2013;32:381–8.

    CAS  PubMed  Google Scholar 

  8. Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, et al. miR-101 suppresses the epithelial-to-mesenchymal transition by targeting zeb1 and zeb2 in ovarian carcinoma. Oncol Rep. 2014;31:2021–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Liu Z, Liu J, Segura MF, Shao C, Lee P, Gong Y, et al. miR-182 overexpression in tumourigenesis of high-grade serous ovarian carcinoma. J Pathol. 2012;228:204–15.

    Article  CAS  PubMed  Google Scholar 

  10. Yu X, Zhang X, Bi T, Ding Y, Zhao J, Wang C, et al. miRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Tumour Biol. 2013;34:3501–8.

    Article  CAS  PubMed  Google Scholar 

  11. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, et al. DNA methylation downregulated miR-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–54.

    Article  CAS  PubMed  Google Scholar 

  12. Li Z, Yu X, Shen J, Jiang Y. MicroRNA dysregulation in uveal melanoma: a new player enters the game. Oncotarget. 2015.

  13. Li Z, Yu X, Shen J, Chan MT, Wu WK. MicroRNA in intervertebral disc degeneration. Cell Prolif. 2015.

  14. Bier A, Giladi N, Kronfeld N, Lee HK, Cazacu S, Finniss S, et al. MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting rtvp-1. Oncotarget. 2013;4:665–76.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Li Z, Yu X, Shen J, Wu WK, Chan MT. MicroRNA expression and its clinical implications in Ewing’s sarcoma. Cell Prolif. 2015;48:1–6.

    Article  PubMed  Google Scholar 

  16. Yu X, Li Z. MicroRNAs regulate vascular smooth muscle cell functions in atherosclerosis (review). Int J Mol Med. 2014;34:923–33.

    CAS  PubMed  Google Scholar 

  17. Yu X, Li Z, Shen J, Wu WK, Liang J, Weng X, et al. MicroRNA-10b promotes nucleus pulposus cell proliferation through rhoc-akt pathway by targeting hoxd10 in intervetebral disc degeneration. PLoS One. 2013;8, e83080.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Lee HK, Finniss S, Cazacu S, Bucris E, Ziv-Av A, Xiang C, et al. Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal. Oncotarget. 2013;4:346–61.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, et al. By downregulating tiam1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2014.

  20. Furuta M, Kozaki K, Tanimoto K, Tanaka S, Arii S, Shimamura T, et al. The tumor-suppressive miR-497-195 cluster targets multiple cell-cycle regulators in hepatocellular carcinoma. PLoS One. 2013;8, e60155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, et al. Increased expression levels of wave3 are associated with the progression and metastasis of triple negative breast cancer. PLoS One. 2012;7, e42895.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Saito A, Suzuki HI, Horie M, Ohshima M, Morishita Y, Abiko Y, et al. Correction: an integrated expression profiling reveals target genes of tgf-beta and tnf-alphah possibly mediated by microRNAs in lung cancer cells. PLoS One. 2014;9.

  23. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in a549 lung cancer cells. Cell Prolif. 2012;45:32–8.

    Article  CAS  PubMed  Google Scholar 

  24. Fu LL, Zhao X, Xu HL, Wen X, Wang SY, Liu B, et al. Identification of microRNA-regulated autophagic pathways in plant lectin-induced cancer cell death. Cell Prolif. 2012;45:477–85.

    Article  CAS  PubMed  Google Scholar 

  25. Luo X, Dong Z, Chen Y, Yang L, Lai D. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated akt pathway. Cell Prolif. 2013;46:436–46.

    Article  CAS  PubMed  Google Scholar 

  26. Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.

    Article  CAS  PubMed  Google Scholar 

  27. Li J, You T, Jing J. MiR-125b inhibits cell biological progression of Ewing’s sarcoma by suppressing the pi3k/akt signalling pathway. Cell Prolif. 2014;47:152–60.

    Article  CAS  PubMed  Google Scholar 

  28. Zhong D, Zhang Y, Zeng YJ, Gao M, Wu GZ, Hu CJ, et al. MicroRNA-613 represses lipogenesis in hepg2 cells by downregulating lxralpha. Lipids Health Dis. 2013;12:32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Zhao R, Feng J, He G. MiR-613 regulates cholesterol efflux by targeting lxralpha and abca1 in ppargamma-activated thp-1 macrophages. Biochem Biophys Res Commun. 2014;448:329–34.

    Article  CAS  PubMed  Google Scholar 

  30. Yang Z, Yuan Z, Fan Y, Deng X, Zheng Q. Integrated analyses of microRNA and mRNA expression profiles in aggressive papillary thyroid carcinoma. Mol Med Rep. 2013;8:1353–8.

    CAS  PubMed  Google Scholar 

  31. Ou Z, Wada T, Gramignoli R, Li S, Strom SC, Huang M, et al. MicroRNA hsa-miR-613 targets the human lxralpha gene and mediates a feedback loop of lxralpha autoregulation. Mol Endocrinol. 2011;25:584–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Hidaka H, Seki N, Yoshino H, Yamasaki T, Yamada Y, Nohata N, et al. Tumor suppressive microRNA-1285 regulates novel molecular targets: aberrant expression and functional significance in renal cell carcinoma. Oncotarget. 2012;3:44–57.

    PubMed  PubMed Central  Google Scholar 

  33. Zhang WH, Gui JH, Wang CZ, Chang Q, Xu SP, Cai CH, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2012;20:139–47.

    Article  CAS  PubMed  Google Scholar 

  34. Wang K, Jia Z, Zou J, Zhang A, Wang G, Hao J, et al. Analysis of hsa-miR-30a-5p expression in human gliomas. Pathol Oncol Res. 2013;19:405–11.

    Article  PubMed  Google Scholar 

  35. Liang J, Zhang Y, Jiang G, Liu Z, Xiang W, Chen X, et al. MiR-138 induces renal carcinoma cell senescence by targeting ezh2 and is downregulated in human clear cell renal cell carcinoma. Oncol Res. 2013;21:83–91.

    Article  PubMed  Google Scholar 

  36. Fei B, Wu H. MiR-378 inhibits progression of human gastric cancer mgc-803 cells by targeting mapk1 in vitro. Oncol Res. 2013;20:557–64.

    Article  CAS  Google Scholar 

  37. Zannoni GF, Improta G, Chiarello G, Pettinato A, Petrillo M, Scollo P, et al. Mutational status of kras, nras, and braf in primary clear cell ovarian carcinoma. Virchows Arch. 2014;465:193–8.

    Article  CAS  PubMed  Google Scholar 

  38. Nodin B, Zendehrokh N, Sundstrom M, Jirstrom K. Clinicopathological correlates and prognostic significance of kras mutation status in a pooled prospective cohort of epithelial ovarian cancer. Diagn Pathol. 2013;8:106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kim M, Chen X, Chin LJ, Paranjape T, Speed WC, Kidd KK, et al. Extensive sequence variation in the 3′ untranslated region of the kras gene in lung and ovarian cancer cases. Cell Cycle. 2014;13:1030–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Natural Science Foundation of China (Grant NO. 81301895) and Shandong Province Natural Science Foundation, China (Grant NO. ZR2012HQ009, NO. ZR2013HQ042)

Author information

Authors and Affiliations

  1. Department of Gynecology Cancer, National Clinical Research Center for Cancer, Tianjin Key Laboratory of Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin, 300060, China

    Xin Fu, Yanfen Cui, Shaobin Yang & Yue Xu

  2. Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Jinan, Shandong, China

    Zicheng Zhang

Authors
  1. Xin Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yanfen Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shaobin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yue Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zicheng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Xin Fu or Zicheng Zhang.

Ethics declarations

Ethics statement

All of the patients provided written informed consent. This study was approved by the Ethics Committee of Tianjin Medical University Cancer Institute and Hospital and complied with the Declaration of Helsinki.

Conflicts of interest

None

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table S1

(DOCX 12 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fu, X., Cui, Y., Yang, S. et al. MicroRNA-613 inhibited ovarian cancer cell proliferation and invasion by regulating KRAS. Tumor Biol. 37, 6477–6483 (2016). https://doi.org/10.1007/s13277-015-4507-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-015-4507-7

Keywords

Search

Navigation